SNDL
SNDLANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Q1 showed the balance sheet remains strong enough to fund buybacks and the Jeeter rollout, and management is steering capital away from the stalled Ontario tranche toward repurchases, which could support per-share value if retail execution stabilizes.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Jeeter rollout and profit-enhancement initiatives may not offset demand weakness quickly enough.
Momentum
99
Value
66
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.55 · Bull $2.25 · Bear $0.95
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.75
Why
Momentum99 · Δ7d -
Value66 · Δ7d +0.1
Sentiment58 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.0
Sentiment
58
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.0 / Value 65.8 / Sentiment 58.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$378.43M
Beta
0.82
Shares Out
257.4M
P/E (TTM) · Derived
-57.9
P/S (TTM)
0.64
P/FCF (TTM)
10.53
Rev YoY
+3.1%
EPS YoY
+29.0%
Gross Margin
+27.0%
Op Margin
-9.7%
Net Debt
-$70.55M
Current Ratio
5.04
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology